Viimane versioon :
06/05/2024
Antiarütmikum   Amiodarone hydrochloride  
Süsteravim
Kapsel Suukaudne lahus
Stabiilsus lahustes Stabiilsust mõjutavad tegurid Stabiilsust mõjutavad faktorid Sobimatus Manustamis viis Viited Pdf
   Keemiline struktuur  

Kaubanduslikud nimed erinevates maades   Kaubanduslikud nimed erinevates maades     

Preparaatide nimed on näitlikud ja abianete sisaldus võib erineda sõltuvalt riigist ja laborist

Acrodarona Ecuador
Amidovin Türgi
Amiocar Argentiina, Maroko
Amiodar Itaalia
Amiodaron Norra, Rootsi, Saksamaa
Amiodarona Argentiina, Ecuador, Kolumbia, Maroko, Mehhiko, Tšiili
Amiodarone Ameerika ühendriigid, Austraalia, Iraan, Itaalia, Kanada, Luksemburg, Suurbritannia, Uus-Meremaa
Amiohexal Saksamaa
Amiokordin Poola, Rumeenia, Ungari
Amiorit Venetsueela
Ancoron Brasiilia
Angoron Kreeka
Asulblan Argentiina
Atlansil Argentiina, Brasiilia, Ecuador, Maroko, Tšiili
Cardasol India
Cardichek India
Cardio Egiptus
Cirtrent Mehhiko
Cordalin Türgi
Cordarex Saksamaa
Cordarone Ameerika ühendriigid, Araabia Ühendemiraadid, Austraalia, Belgia, Ecuador, Holland, Iirimaa, Island, Itaalia, Kolumbia, Luksemburg, Malaisia, Maroko, Mehhiko, Norra, Poola, Portugal, Prantsusmaa, Rootsi, Saudi Araabia, Soome, Suurbritannia, Sveits, Taani, Tšiili, Tuneesia, Türgi, Ungari, Uus-Meremaa
Duron India
Eudarona Venetsueela
Eurythmic India
Farcodarone Egiptus
Ronecard Egiptus
Sedacoron Austria, Poola, Rumeenia, Saudi Araabia, Tuneesia
Sedacorone Iraan
Trangorex Hispaania, Venetsueela
Viited   Süsteravim   Viited : Amiodarone hydrochloride  
Tüüp Avaldamine
200 Ajaleht Korth-Bradley JM, Ludwig S, Callaghan C.
Incompatibility of amiodarone hydrochloride and sodium bicarbonate injections.
Am J Health-Syst Pharm 1995 ; 52: 2340.
205 Ajaleht Strozyk WR, Williamson R, Thompson D.
Incompatibility of amiodarone hydrochloride and evacuated glass bottles.
Am J Health-Syst Pharm 1996 ; 53: 184.
242 Ajaleht Campbell S, Nolan PE, Bliss M, Wood R, Mayersohn M.
Stability of amiodarone hydrochloride in admixtures with other injectable drugs.
Am J Hosp Pharm 1986 ; 43: 917-921.
295 Ajaleht Yamashita SK, Walker SE, Choudhury T, Iazzetta J.
Compatibility of selected critical care drugs during Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1048-1051.
379 Ajaleht Weir SJ, Szucs Myers VA, Bengtson KD, Ueda CT.
Sorption of amiodarone to polyvinyl chloride infusion bags and administration sets.
Am J Hosp Pharm 1985 ; 42: 2679-2683.
385 Ajaleht Benedict MK, Roche VF, Banakar UV, Hilleman DE.
Visual compatibility of amiodarone hydrochloride with various antimicrobial agents during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1117-1118.
647 Ajaleht Pramar YV.
Chemical stability of amiodarone hydrochloride in intravenous fluids.
Int J Pharm Compound 1997 ; 1: 347-348.
925 Ajaleht Dupuis LL, Trope A, Giesbrecht E, Wong B.
Compatibility and stability of propafenone hydrochloride with five critical-care medications.
Can J Hosp Pharm 1998 ; 51: 55-57.
1036 Ajaleht Hasegawa GR, Eder JF.
Visual compatibility of amiodarone hydrochloride injection with other injectable drugs.
Am J Hosp Pharm 1984 ; 41: 1379-1380.
1041 Ajaleht Hasegawa GR, Eder JF.
Visual compatibility of dobutamine hydrochloride with other injectable drugs.
Am J Hosp Pharm 1984 ; 41: 949-951.
1232 Ajaleht Beatson C, Taylor A.
A physical compatibility study of furosemide & flucloxacillin injections.
Br J Pharm Pract 1987 ; 9: 223-226, 236.
1508 Ajaleht Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F.
Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU.
EJHP 2015 ;22:123-124.
1611 Ajaleht Chalmers JR, Bobek MB, Militello MA.
Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs.
Am J Health-Syst Pharm 2001 ; 58: 504-506.
1712 Ajaleht Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233.
1713 Ajaleht Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315.
1721 Ajaleht Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72.
1733 Ajaleht Kopelent-Frank H, Schimper A.
HPTLC-based stability assay for determination of amiodarone in intravenous admixtures.
Pharmazie 1999 ; 54: 542-544.
1801 Ajaleht Feddema S, Rusho WJ, Tyler LS, Barker B.
Physical compatibility of vasopressin with medications commonly used in cardiac arrest.
Am J Health-Syst Pharm 2003 ; 60: 1271-1272.
1803 Ajaleht Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85.
1963 Ajaleht Honisko ME, Fink JM, Militello MA, Mauro VF, Alexander KS.
Compatibility of argatroban with selected cardiovascular agents.
Am J Health-Syst Pharm 2004 ; 61: 2415-2418.
2090 Ajaleht Pere H, Chasse V, Forest JM, Hildgen P.
Compatibility of injectable pantoprazole in Y-site administration.
Pharmactuel 2004 ; 37: 193-196.
2108 Ajaleht Trusley C, Kupiec TC, Trissel LA.
Compatibility of micafungin injection with other drugs during simulated Y-site co-administration.
Int J Pharm Compound 2006 ; 10: 230-232.
2109 Ajaleht Pelletier E, Forest JM, Hildgen P.
Compatibilité de la kétamine injectable lors de l’administration en dérivé avec d’autres médicaments usuels.
Pharmactuel 2006 ; 39: 71-75.
2139 Ajaleht Serrurier C, Chenot ED, Vigneron J, May I, Demor? B.
Assessment of injectable drug’s administration in two intensive care units and determination of potential physico-chemical incompatibilities.
EJHP Science 2006 ; 12,5: 96-99.
2146 Ajaleht Trissel LA, Xu QA, Baker M.
Drug compatibility with new polyolefin infusion solution containers.
Am J Health-Syst Pharm 2006 ; 63: 2379-2382.
2247 Ajaleht Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262 Ajaleht Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269 Ajaleht Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2346 Ajaleht Newland A.M, Mauro V.F, Alexander K.S.
Physical compatibility of metoprolol tartrate injection with selected cardiovascular agents
Am J Health-Syst Pharm 2009 ; 66: 986-987.
3012 Ajaleht Sullivan T, Forrest J.M, Leclair G.
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration
Hosp Pharm 2015 ; 50, 3: 214-220.
3134 Ajaleht Perez Jua En, Maqueda Palau M, Arévalo Rubert Mt, Ribas Nicolau B, Amoros Cerdà SM.
Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua.
Enferm Intensiva 2010 ; 21: 96-103.
3210 Ajaleht Jasti Bhaskara R, Saraf Poonam.
Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations.
Int J Pharm Compound 2011 ; 15, 3: 259-261.
3212 Ajaleht Ribas Nicolau, B.; P?rez Juan, E.; Amor?s Cerd?, S.M.; Ar?valo Rubert, M.J.; Maqueda Palau, M.
Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos.
Enferm Intensiva 2011 ;22:78-82.
3216 Ajaleht Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G.
Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y.
Pharmactuel 2011 ; 44, 1 : 14-18
3249 Ajaleht Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3372 Ajaleht Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S.
Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine.
Rev Bras Anestesiol 2013 ; 63, 1: 163-166.
3379 Ajaleht Fox L.M, Wilder A.G, Foushee J.A.
Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration.
Am J Health-Syst Pharm 2013 ;70:520-524.
3381 Ajaleht Humbert-Delaloye V, Berger-Gryllaki M, Voirol P, Gattlen L, Pannatier A.
In vitro compatibility of various cardioactive drugs during simulated Y-site administration.
EJHP 2013 ; 20:110-116.
3408 Ajaleht Tollec S, Touzin K, Pelletier E, Forest J.M.
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Pharmactuel 2013 ; 46, 1 : 16-21.
3463 Ajaleht Eva Perez Juan, Maria Jos? Arévalo Rubert , Silvia Monica Amoros Cerda , Palau M.M, Nicolau B.R.
Fármacos en perfusión continua en la unidad de cuidados intensivos: estudio de compatibilidad.
Nursing 2011 ; 29 :62-6
3464 Ajaleht Monica Maqueda-Palau, Eva Pérez-Juan, Maria Josep Arévalo-Rubert, Sylvia Monica Amoros-Cerda, Bàrbara Ribas-Nicolau.
Compatibilidad física de la amiodarona en perfusión continua
Enferm Clin 2011 21:25-29.
3465 Ajaleht E. P?rez Juan, M. Maqueda Palau, M. Ar?valo Rubert, B. Ribas Nicolau, S.M. Amor?s Cerd?.
Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua.
Enferm Intensiva 2010 ;21:96-103.
3466 Ajaleht B. Ribas Nicolau, E. P?rez Juan, S.M. Amor?s Cerd?, M.J. Ar?valo Rubert, M. Maqueda Palau.
Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos
Enferm Intensiva 2011 ;22:78-82.
3524 Labor Amiodarone hydrochloride (Cordarone®) - Summary of Product Characteristics.
Sanofi 2013
3539 Labor Bivalirudin (Angiox®) - Summary of Product Characteristics.
The Medecines Company 2013
3540 Labor Heparin sodium - Summary of Product Characteristics.
Wockhardt 2010
3766 Ajaleht Forrest J.M, Hildgen P.
Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels
Pharmactuel 2014 ; 47, 3 : 161-165.
3767 Ajaleht Legris M.E, Lavoie A, Forrest J.M, Hildgen P.
Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels.
Pharmactuel 2014 ; 47, 3 : 167-172.
3823 Ajaleht Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R.
Compatibilité physique de médicaments administrés dans l’unité de soins intensifs
Pharmactuel 2015 ; 48, 3 : 146-152.
3824 Ajaleht Boudi S, Roy H, Forest JM, Leclair G.
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Pharmactuel 2023 2023;56,3:91-98
3827 Plakat Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015
3828 Plakat Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 Plakat So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
3932 Labor Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit
Serb Laboratoire 2015
3964 Ajaleht Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33.
4055 Ajaleht Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4119 Plakat Marcoz N, Ing H, Sautter AM, Saadi JF, Roulin JF, Bonnabry P.
Stabilité et compatibilité de solutions injectables d'amiodarone (Cordarone®)
Hôpitaux Universitaire de Genève 2004
4130 Ajaleht Koller AK, Krebs S, Dörje F.
Untersuchungen zur Kompatibilität von Clonidin mit häufig eingesetzen Arzneimittel auf Intensivstationen.
Pharmaceutics 2021 , 13, 21.
4145 Ajaleht Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4252 Ajaleht Lardinois B, Dimitriou A, Delcave C, Jamart J, Bihin B, Soumoy L, Hecq JD, Galanti LM.
Evaluation of the Physicochemical Stability of Amiodarone Hydrochloride in Syringes for the Intensive Care Unit.
Int J Pharm Compound 2019 ;23,2:163-166
4319 Ajaleht Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337.
4354 Plakat Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R.
Compatibilité visuelle du Vyxeos lors d'administration en Y avec une sélection de médicaments injectables.
GERPAC Congress 2019 2019
4371 Ajaleht Mediavilla MM, Molina A, Navarro L, Grau L, Pujol MD, Cardenete J, Cardona D, Riera P.
Physicochemical Compatibility of Amiodarone with Parenteral Nutrition.
Journal of Parenteral and Enteral Nutrition 2018
4411 Ajaleht Wilder A.G, Foushee J.A, Fox L.M, Navalle J, Wright A.M, Greer M.A.
Physical Compatibility of Medications Used in Critically Ill Patients with Balanced Fluid Solutions.
Int J Pharm Compound 2020 ;24,3:238-241.
4434 Ajaleht Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L.
Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.
Clin Ther 2019 ; 41, 10: 2162-2170.
4491 Ajaleht De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pilar P, De Miguel M, Campino A.
Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units.
Eur J Pedia 2020
4506 Ajaleht Griffith S, Stapleton E, Padilla S, Mruk A, Thomas C.
Physical compatibility of milrinone 1 mg/mL with select cardiovascular medications during simulated Y-site administration.
Am J Health-Syst Pharm 2020 ;77,23:1938-1940.
4528 Ajaleht Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4603 Ajaleht Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234.
4650 Labor Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021
4651 Ajaleht De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pascual P, De Miguel M, Campino A.
Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units.
Eur J Pedia 2021 ;180,1169–1176.
4655 Ajaleht Holyk A, Lindner A, Lindner S, Shippert B
Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration.
Am J Health-Syst Pharm 2022 ;79,1:27-33
4698 Ajaleht Ayari G, D'Huart E, Vigneron J, Demoré B.
Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs.
Pharmaceutical Technology in Hospital Pharmacy 2022
4742 Ajaleht Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255.

  Mentions Légales